akayasu arteritis (TA) is a chronic vasculitis that affects the aorta and its primary branches such as the brachiocephalic, carotid, subclavian, vertebral, and renal arteries, as well as the coronary and pulmonary arteries. 1, 2 The disease prevalence of TA is higher in South-East Asia, India and South America, than in other regions of the world. 3- 7 The inflammatory processes cause occlusion, stenosis, and dilatation at the portions of the arteries involved. 8 The etiology of this disease is still unknown, but previous studies have indicated that genetic factors and cellular immunity may play a role in its pathogenesis. 9, 10 
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The role of human leukocyte antigen (HLA) in TA has been well investigated, with different alleles in different populations. [11] [12] [13] [14] In the Japanese population, the HLA-B52 and -B39 haplotypes are closely associated with susceptibility to TA. 15, 16 In addition, it has been suggested that the presence of specific HLA-B alleles is related to clinical manifestations of TA. 17, 18 More than 15 years have passed, however, since those results were reported. Recent progress in DNA sequencing technology has enabled greater detailed assays for HLA typing, as well as higher accuracy. The nomenclature and classification of HLA typing have been evolving in tandem with these advances. Also, recent advances in imaging have enabled us to detect more subtle vascular complications than before. These advances have altered the concept of the clinical features of this disease.
To further clarify the correlation of TA with HLA alleles using recent methods of HLA genotyping, we have re-examined the HLA haplotypes and compared clinical characteristics in Japanese patients with TA at a single center.
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TAKAMURA C et al. study. As controls, we used a database of HLA allele frequency in the general Japanese population, which includes a total of 371 individuals. 20 The study protocol was approved by the ethics committee of Tokyo Medical and Dental University. All study participants provided their informed consent.
Clinical Characteristics
We investigated 7 clinical characteristics: age at disease onset; distribution of arterial lesion; pulmonary involvement; aortic regurgitation; systemic hypertension; steroid resistance; and recurrence rate. Angiography, such as digital subtraction angiography or computed tomography or magnetic resonance angiography, was used to define the location of the arteries involved in TA. Aortic regurgitation was diagnosed on angiography or echocardiography, and was graded as moderate or severe. Systemic hypertension was defined as a systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg. Steroid resistance was defined as a situation in which additional immunosuppressive agents or biological agents were required due to inability of glucocorticoid therapy alone to provide sustained remission. Recurrence was defined as multiple relapses or clinical deterioration while receiving conventional therapy.
HLA Genotyping
Genomic DNA was extracted from white blood cells by standard techniques using ethylene diamine tetra-acetic acid. 21 All of the DNA samples were analyzed for HLA genotypes (HLA-A, -B, -C, DPB1, DQB1 and DRB1 locus) with the direct sequencing of polymerase chain reaction amplicons encompassing exon 2 through intron 4 of the HLA class I locus and exon 2 in HLA class II (Allele SEQR, Abbott Molecular Inc). Regarding the HLA-DQA1 locus, we assayed them using PCR-SSP kit (Invitrogen).
Statistical Analysis
The allele frequencies of each HLA were compared between TA patients and controls using the chi-square test. Odds ratios (OR) and 95% confidence intervals were calculated using Woolf's method. Continuous variables in clinical data are given as mean ± SD. The significant differences between groups were assessed using the independent Student's t-test for continuous variables and evaluated with chi-square test for categorical ones. P<0.05 was considered to indicate statistical significance.
Results

HLA-DNA Typing
The frequency of each HLA-A, -B, -C, DRB1 and DQB1 allele in TA patients and controls is shown in Table 2 is a subset of Table 1 with addition of adjusted P-value information for the 3 alleles of highest interest. It shows that the frequencies of HLA-B67 and B52 alleles were significantly higher in TA patients than in controls. The frequency of the HLA-B39 allele, however, which has been reported to be associated with TA in Asian populations, was not higher in the present TA patients (P=0.86, OR=1.07).
Association of Clinical Characteristics of TA With HLA-B67 and HLA-B52
Whether clinical characteristics of TA differed according to presence of HLA-B67 is shown in Table 3 . There was no significant difference in those clinical parameters between HLA-B67-positive patients and -negative patients. We compared these same clinical parameters in TA patients positive for HLA-B67 and HLA-B52. These data included the 3 patients who had both alleles, HLA-B67 and B52, but again, no significant differences were observed in clinical characteristics. Also there were no significant differences between HLA-B67-positive patients and both HLA-B67-and -B52-negative pa- 
Discussion
In the present study, we found HLA-B67 alleles to be significantly associated with TA in Japanese patients. Its prevalence was lower than HLA-B52, a conventional risk allele for TA in Japanese populations, but its OR was higher than that for HLA-B52. To our knowledge, this is the first study to report an association between HLA-B67 and TA in the Japanese population or other ethnic groups. The correlation of different HLA alleles and TA has been described in different populations. 11-16 For example, in Japan HLA-B52, -B39, DRB1*1502, DRB5*0102, DQA1*0103, DQB1*0601, and DPB1*0901 are strongly associated with TA. 11,15, 16 Kimura et al found that DPB1*0901 and HLA-B52 had a strong linkage disequilibrium, 16 so it has been suggested that HLA-B alleles might have stronger association with TA than the HLA class II alleles. In the present study, from the comparison of OR, HLA-B67 and -B52 were confirmed to be strongly associated with TA. The frequency of the HLA-B52 allele was 28.6% (55/192 alleles) vs. 10.7% of controls. In contrast, that of the HLA-B67 allele was 5.2% (10/192) compared to 1.1% in controls. Therefore, B52 could be a more sensitive marker for diagnosis of TA. Because of higher OR, the presence of HLA-B67 apparently is a more specific marker of TA as compared to B52. But the frequency of HLA-B67 was low, therefore it is necessary to confirm conclusively by increasing the number of cases.
HLA-B67 is a specific HLA genotype for East Asian people 22 and it has not been reported in African or Caucasian subjects. One study in China demonstrated that HLA-B67 was a male-specific HLA marker of susceptibility to relapsed childhood acute lymphoblastic leukemia. 23 The presence of this allele may suggest the susceptibility not only to TA but also to other diseases, especially in Asia.
There have been some reports about the relationships between clinical characteristics of TA and HLA alleles. Kasuya et al showed that TA with HLA-B52 resulted in a higher incidence of coronary artery disease and a worse prognosis. 24 Kitamura et al also reported that aortic regurgitation, pulmonary infarction and ischemic heart disease were frequently found in HLA-B52-positive and -B39-negative TA patients. 18 In the present study, we compared clinical parameters in TA patients with HLA-B67 and HLA-B52, but found no significant differences among groups with or without these alleles alone or in combination as compared to other patients. HLA-B67 and -B52 alleles were not related to locations of arteritis. Our recent report also showed that there was no difference in the distribution of vascular involvement and other clinical characteristics between patients with and without the HLA-B52 allele. 25 The reasons for difference between the present study and previous studies should be considered. During the last 2 decades, imaging modalities including ultrasound, magnetic resonance, computed tomography and positron emission tomography have progressed a great deal, allowing us to diagnose early and subtle changes of the arterial wall in TA. We sometimes detect TA without any significant stenosis or dilatation of major arteries. Also, recent imaging tests sometimes show unexpected extension of arterial inflammation in apparently normal arteries. These advances in diagnostic technology might alter the currently known rates of diagnosis and complications and clinical course and consequently affect the observation of the relationship between clinical features and presence of specific alleles such as B52 in TA.
We could not find any statistical difference in the prevalence of B39 between TA patients and the Japanese population, although B39 has been known as one of the specific risk alleles for TA for nearly 2 decades. One of the major differences between the original report and the present study is the prevalence of B39 antigen (B3901 allele) in normal controls. Yoshida et al reported in 1993 that B39.2 could not be found in any of 156 Japanese controls, 15 whereas a recent report by Saito et al, 20 which we used for this study as our control population, showed that 33 of 371 Japanese controls (8.9%) had B39 (B3901 allele). The 9.4% prevalence of B39-positive TA patients in the present study is similar to that reported by Yoshida et al (6.4%). Therefore, the difference between the results of the 2 studies likely rests on the difference in the prevalence of B39 in the respective control populations. Although we cannot address the nature of the difference, further investigation is needed to clarify the difference.
Kimura et al also reported an association between B39 and TA. 16 They pointed out an association with B39.2 but not with B39.1. This nomenclature, however, is not used any more. We Table 1 . TAKAMURA C et al.
used the current nomenclature of B39 antigen, which includes B3901, B3902, B3904 and B3923 alleles. All of the 9 patients who had B39 in the present study had the B3901 allele. Although we cannot follow the association of B39.1 and B3901, from our data we are convinced that B3901 and other B39 alleles are not associated with TA. We should be cautious in using B39 for diagnostic use or investigation of genetic background for TA until its ultimate clinical significance is settled.
We note that in this study, 2 cases of familial TA were included. From analysis of HLA-DNA typing, HLA-B52 and DRB1*1502, DQB1*0601 and DPB1*09, which have been reported to be associated with TA, were found in those cases. There have been some reports that focused on the association between HLA and familial TA, 26-28 but many of these remain unconfirmed and vary across different ethnic groups. The present results, however, suggest that hereditary factors may play an important role in the pathogenesis of TA.
